Viewing Study NCT03135951


Ignite Creation Date: 2025-12-24 @ 11:47 PM
Ignite Modification Date: 2026-01-05 @ 6:03 PM
Study NCT ID: NCT03135951
Status: COMPLETED
Last Update Posted: 2020-11-13
First Post: 2017-04-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Sponsor: Spectrum Pharmaceuticals, Inc
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module